<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078658</url>
  </required_header>
  <id_info>
    <org_study_id>NU21-01-00085</org_study_id>
    <nct_id>NCT05078658</nct_id>
  </id_info>
  <brief_title>Low-carbohydrate Diet in Children With Type 1 Diabetes</brief_title>
  <acronym>Lowca</acronym>
  <official_title>Low-carbohydrate Diet in Paediatric Type 1 Diabetes: Effects on Glycaemic Control and Islet Autoimmunity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Motol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Czech Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Motol</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this pilot study is to test whether low-carbohydrate diet (LCD) instituted&#xD;
      in children/adolescents with type 1 diabetes (T1D) can improve their disease control. The&#xD;
      primary objective of the trial is the change in continuous glucose monitoring time in target&#xD;
      range 3.9-10.0 mmol/l (TIR) in a 5-week period on LCD as opposed to a 5-week period on&#xD;
      recommended carbohydrate diet (RCD).&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
      Changes in immune parameters during the LCD period; Differences in fecal microbiome during&#xD;
      the LCD period; Differences in fecal, serum and urine metabolome during the LCD period;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in continuous glucose monitoring time in target range (3.9-10.0 mmol/l) during the LCD period compared to the RCD period</measure>
    <time_frame>Month 1 - Month 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in mean insulin dose during the LCD period compared to the RCD period</measure>
    <time_frame>Month 1 - Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mean body weight standard deviation score during the LCD period compared to the RCD period</measure>
    <time_frame>Month 1 - Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the lipid spectrum during the LCD period compared to the RCD period</measure>
    <time_frame>Month 1 - Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in muscle strength measured by jumping mechanography during the LCD period compared to the RCD period</measure>
    <time_frame>Month 1 - Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lymphocyte subgroup cell counts (flow cytometry) during the LCD period</measure>
    <time_frame>Month 1 - Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in faecal microbiome between the LCD and RCD periods</measure>
    <time_frame>Month 1 - Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in faecal metabolome between the LCD and RCD periods</measure>
    <time_frame>Month 1 - Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in serum metabolome between the LCD and RCD periods</measure>
    <time_frame>Month 1 - Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in urine metabolome between the LCD and RCD periods</measure>
    <time_frame>Month 1 - Month 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>Low-carbohydrate diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recommended carbohydrate diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories with 50% (+/- 5%) of the recommended energy from carbohydrates.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-carbohydrate diet</intervention_name>
    <description>The diet will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.</description>
    <arm_group_label>Low-carbohydrate diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Recommended-carbohydrate diet</intervention_name>
    <description>The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories with the amount of carbohydrates equal to 45% (+/- 5%) of the recommended energy a day.</description>
    <arm_group_label>Recommended carbohydrate diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T1D diagnosed according to the ADA (American Diabetes Assocciation) criteria&#xD;
&#xD;
          -  T1D duration for at least 1 year prior to the intervention&#xD;
&#xD;
          -  continuous glucose monitor (CGM) worn &gt; 70% time in the month prior to the&#xD;
             intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  last HbA1c &lt; 40 or &gt; 70 mmol/mol&#xD;
&#xD;
          -  subject has celiac disease&#xD;
&#xD;
          -  daily average carbohydrate intake &lt; 130 g/day from 14 days food record prior to the&#xD;
             intervention&#xD;
&#xD;
          -  any concomitant disease possibly affecting glucose control&#xD;
&#xD;
          -  any chronic medication possibly affecting glucose control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zdenek Sumnik, Prof.</last_name>
    <phone>+420702000087</phone>
    <email>zdenek.sumnik@lfmotol.cuni.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <zip>CZ-15600</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zdenek Sumnik, Prof.</last_name>
      <phone>+420702000087</phone>
      <email>zdenek.sumnik@lfmotol.cuni.cz</email>
    </contact>
    <contact_backup>
      <last_name>Vit Neuman, Dr.</last_name>
      <phone>+420773608308</phone>
      <email>Vit.Neuman@fnmotol.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Vit Neuman, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Motol</investigator_affiliation>
    <investigator_full_name>Zdeněk Šumník</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

